We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





AACC Survey Finds Nearly Half of All US Labs Still Do Not Have Supplies for Running COVID-19 Tests

By LabMedica International staff writers
Posted on 30 Jul 2020
Print article
Illustration
Illustration
A new survey of clinical laboratories in the US has found that nearly half of all responding labs still do not have the supplies they need to run COVID-19 tests.

The survey was conducted by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) which has presented its findings to the White House Coronavirus Task Force, calling on the federal government to take a more active role in alleviating this problem, so that labs can increase their testing capacity in the midst of the virus’s latest surge.

As coronavirus cases in the US soar, the country’s labs have continued to work tirelessly to ramp up testing to help bring the pandemic under control. However, even though US labs are now performing an average of 800,000 COVID-19 tests per day, which is double the average daily number of tests performed in late May, labs in many areas are reporting delays of up to a week in getting test results back to patients. These delays render testing essentially useless in acute patient care and in contact tracing. The main cause of these crippling delays is the persistent shortage of testing and other essential supplies.

AACC conducted a survey to determine the full extent of these supply shortages and how they are changing as the pandemic progresses, in the hopes that this information can help guide the federal government’s response. AACC surveyed clinical labs across the US about this issue during three different time periods: May 1-24, June 1-5, and June 24-July 6. The results showed a troubling trend, namely that supply shortages have persisted over the last few months. In May, 58% of all labs surveyed reported problems getting supplies, a figure that only decreased to 46% by early July. Even more worrying was a rise in the number of labs that are unable to process all requested COVID-19 tests within a week because of supply shortages. In early July, 25% of respondents reported this problem, an uptick from 21% of respondents in May.

The specific supplies that labs have the most difficulty obtaining are COVID-19 test kits and the reagents, or chemicals, used to perform these tests. As of early July, 58% of labs reported problems getting test kits, while 46% reported problems getting reagents. 38% of labs also still reported problems getting the nasal swabs used to obtain patient samples for COVID-19 testing. In fact, out of all the items that respondents had difficulty obtaining in May, personal protective equipment (PPE) is the only one that was not in short supply in late June/early July. While 32% of labs had problems getting PPE in May, only 4% reported having this issue in the most recent survey.

“We at AACC are deeply concerned that clinical labs continue to struggle with obtaining the supplies needed to meet our nation’s COVID-19 diagnostic testing demands,” said AACC President Dr. Carmen Wiley. “While we recognize the difficulty the federal government is encountering with this pandemic, we urge the Task Force to use the data from AACC’s survey as a jumping off point to investigate these ongoing shortages, and to use the authority of the federal government to obtain and allocate these vital supplies.”

Related Links:
American Association for Clinical Chemistry (AACC)

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.